• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties

    1/20/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email

    NASDAQ | TSX: ACB

    European grant advances Aurora's unparalleled leadership in cannabis genetics, enhancing its position as a leading medical cannabis company

    EDMONTON, AB, Jan. 20, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today announces that it has been granted community plant variety rights by the EU's Community Plant Variety Office for two of its proprietary cannabis varieties. This achievement further strengthens the company's intellectual property portfolio and reinforces its commitment to innovation and cannabis genetics excellence.

    Aurora Logo (CNW Group/Aurora Cannabis Inc.)

    Bred in Canada through Aurora's advanced breeding and phenotyping programs, the company has been granted plant variety rights to Cannabis sativa L varieties named SOT20R07-007 (known as Farm Gas™) and ACB21T044 (known as Sourdough™). These varieties and their traits are the result of the company's research expertise and rigorous scientific standards. Both cultivars are recognized for their strong patient and consumer appeal – including high potency and desirable aromas and bud structure – as well as for their consistency, and strong performance traits. Farm Gas™ and Sourdough™ are core products available to medical patients in Germany, Poland, UK, Canada, and Australia.

    "Being granted Community Plant Variety Rights in the EU is a direct recognition of the exceptional cannabis genetics work underway at our preeminent Aurora Coast R&D facility that is unmatched in its level of excellence," said Lana Culley, VP of Innovation and International Operations for Aurora. "This protection not only strengthens Aurora's global genetics portfolio, but also ensures that our high-quality, differentiated varieties can consistently reach patients and consumers worldwide. Aurora remains committed to advancing our unique breeding program and developing genetics that set new standards in cannabis cultivation."

    Community Plant Variety Rights, give Aurora exclusive control over the commercial production and sale of these varieties throughout the European Union's 27 member states for the duration of the protection period. Obtaining these rights in the EU, as well as existing rights in Canada and other territories, enables Aurora to commercialize the company's cultivars globally while protecting investments in science and innovation. Aurora's cultivars are grown in our own network of cultivation sites, as well as grown by partners and licensees around the world.

    Aurora's robust genetics platform underpins its global medical cannabis leadership and supports the company's ability to deliver consistent, reliable, and premium products. The protection of these varieties enhances Aurora's competitive position in Europe, a fast-moving and highly valuable region to the company.  

    About Aurora Cannabis Inc.

    Aurora is Opening the World to Cannabis™, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift®, San Raf®, Daily Special™, Tasty's™, Being® and Greybeard®. Medical cannabis brands include MedReleaf®, CanniMed®, Aurora® and Whistler Medical Marijuana Corporation®, as well as international brands, Pedanios®, IndiMed™ and CraftPlant™. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

    Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

    Forward Looking Information  

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the community plant variety rights granted to the Company by the EU's Community Plant Variety Office for two of its proprietary cannabis varieties and the associated benefits, including the strengthening of Aurora's global genetics portfolio, the Company's ability to commercialize its cultivars globally while protecting investments in science and innovation, and the enhancement of Aurora's competitive position in Europe; as well as statements regarding the Company's continued commitment to innovation and cannabis genetics excellence, the Company's global medical cannabis leadership and the Company's ability to deliver consistent, reliable, and premium products.

    These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-secures-eu-community-plant-variety-rights-for-two-proprietary-cannabis-varieties-302663664.html

    SOURCE Aurora Cannabis Inc.

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurora Cannabis to Host Third Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Jan. 21, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2026 on Wednesday, February 4, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 4, 2026 TIME: 8:00 a.m. Eastern Time |

    1/21/26 4:35:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties

    NASDAQ | TSX: ACB European grant advances Aurora's unparalleled leadership in cannabis genetics, enhancing its position as a leading medical cannabis company EDMONTON, AB, Jan. 20, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today announces that it has been granted community plant variety rights by the EU's Community Plant Variety Office for two of its proprietary cannabis varieties. This achievement further strengthens the company's intellectual property portfolio and reinforces its commitment to innovation and cannabis genetics excellence.

    1/20/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Achieves Significant Progress in Disease Resistance Research

    NASDAQ | TSX: ACB As a leading global medical cannabis company, advancements in breeding, testing and production trials for powdery mildew-resistant cultivars reinforce Aurora's leadership in cannabis science EDMONTON, AB, Jan. 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce significant progress in its powdery mildew (PM) resistance research, nearly one year after the company's breakthrough discovery of a novel source of genetic resistance against powdery mildew, PM2. Since

    1/14/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Aurora Cannabis

    Canaccord Genuity initiated coverage of Aurora Cannabis with a rating of Buy

    1/27/26 9:29:20 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    TD Cowen initiated coverage on Aurora Cannabis

    TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

    12/11/24 10:35:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

    2/9/24 6:09:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    1/21/26 5:17:54 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    1/14/26 7:22:12 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    11/5/25 7:25:30 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Financials

    Live finance-specific insights

    View All

    Aurora Cannabis to Host Third Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Jan. 21, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2026 on Wednesday, February 4, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 4, 2026 TIME: 8:00 a.m. Eastern Time |

    1/21/26 4:35:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

    Expands YoY Global Medical Cannabis Net Revenue1 by 15% to Record $70.5 millionIncreases International Medical Cannabis Net Revenue1 by 22% to Record $42.7 million, with leadership positions across key marketsDelivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.

    11/5/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Oct. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on Wednesday, November 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, November 5, 2025 TIME: 8:00 a.m. Easte

    10/22/25 5:15:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    View All

    Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand

    NASDAQ | TSX: ACB EDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries. "I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicated

    12/8/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Announces Distribution Partnership with Leafio Australia

    The collaboration will improve medical cannabis access and better serve patients across Australia NASDAQ | TSX: ACB EDMONTON, AB, Dec. 2, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia. This strategic partnership will expand patient access to trusted, safe, and effective medical cannabis across Australia, while supporting healthcare professionals with educational resources. Leafio will serve as a wholesaler of Aurora's leading portfoli

    12/2/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Rubicon Organics Announces Appointment of Glen Ibbott as CFO

    VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary. "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impac

    11/12/25 8:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/23 11:28:04 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Aurora Cannabis Inc.

    SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

    6/1/22 10:14:29 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/22 3:54:29 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care